2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2311

Safety of Pregabalin for Treatment of Fibromyalgia Is Comparable Between Subjects with Moderate or Severe Baseline Widespread Pain
Abstract Number: 2312

Patient Preferences for Total Knee Replacement Surgery: Two Year Follow-up
Abstract Number: 2313

Responder Rates and Numbers Needed to Treat Based on Clinically Meaningful Improvements in Patient Reported Outcomes (PROs) Including Health-Related Quality of Life (HRQoL) after Sarilumab Treatment during a Phase III Randomized Controlled Trial (RCT)
Abstract Number: 2314

Minimal Important Difference in HAQ: A Validation from Health Economic Perspectives in Patient with Rheumatoid Arthritis Using Real-World Data
Abstract Number: 2315

Six-Month Effects of a Multimedia Patient Education Tool in Patients with Rheumatoid Arthritis. a Randomized Controlled Trial
Abstract Number: 2316

An Ethnographic Observational Study of the Biologic Initiation Conversation Between Rheumatologists and Biologic Naïve Rheumatoid Arthritis Patients
Abstract Number: 2317

Different Rheumatoid Arthritis Disease Activity Measures Often Provide Discordant Results in Clinical Practice Populations
Abstract Number: 2318

Inflammatory Arthritis Patient Perspectives on Strategies to Support Medication Adherence: A Qualitative Study Using a Novel Group Exercise
Abstract Number: 2319

Mobile Medical Documentation of Patient-Reported-Outcome
Abstract Number: 2320

The Use of Doppler Ultrasound in Patients with Rheumatoid Arthritis Improves Patient Understanding of Disease and Adherence to Treatment and Alters Clinical Practice
Abstract Number: 2321

Performance of Patient Reported Outcomes in the Assessment of Rheumatoid Arthritis Disease Activity: The Experience of the Espoir Cohort
Abstract Number: 2323

Patient Priorities in Rheumatoid Arthritis (RA) Research: An Exploration of Patient Perspectives from Those Enrolled in an Ontario RA Cohort
Abstract Number: 2324

Understanding the Importance of a Patient’s Role in the Management of RA: Results from a Patient-Based Survey
Abstract Number: 2325

Quantitative Clues to Recognize and Document Comorbid Fibromyalgia in Routine Care of Patients with Other Rheumatic Diagnoses on a 10 Cm Distress Visual Analog Scale Found on 1-Page Physician Rheumetric Checklist
Abstract Number: 2326

Patient Preferences Regarding Route of Biologic Administration in an Inflammatory Arthritis Cohort

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].